Table 1.
Economic efficacy of component-resolved diagnosis based on allergen molecules versus SPT for AIT treatment for patients with pollen-induced allergic rhinitis (n = 95)
| Skin prick testing | ImmunoCAP | Economic efficacy | |
|---|---|---|---|
| Diagnostic cost, EUR | |||
| Per patient | 23.4 | 92.20 | −68.80 |
| For the group | 2,223.0 | 8,759 | −6,536.00 |
| AIT prescription, n (%) | |||
| 1 extract | 0 (0) | 66 (69.4) | |
| 2 extracts | 10 (10.5) | 24 (25.3) | |
| 3 extracts | 85 (89.5) | 5 (5.3) | |
| Mean extracts per patient | 2.9 | 1.3 | |
| AIT cost, EUR | |||
| Per year per patient | 370.76 | 173.92 | 196.84 |
| Per 3 years per patient | 1,112.30 | 521.77 | 590.53 |
| Total cost (diagnostic/AIT), EUR | |||
| Per patient | 1,135.70 | 613.97 | 521.73 |
| For the group | 107,891.50 | 58,327.15 | 49,564.35 |
SPT, skin prick testing; AIT, allergen-specific immunotherapy.